Reduction of L O-ag production and antigenic shift to O2-antigen in by Fermin E. Guerra (6084545)

Patient demographics. by Katrine Carlsen (5477300)

Subjects:

Association across weeks to treatment for three genera. by Katrine Carlsen (5477300)

Subjects:

Genera associated with FC, symptom score or week to treatment. by Katrine Carlsen (5477300)

Subjects:

Changes in alpha diversity in the weeks before anti-TNF-a treatment. by Katrine Carlsen (5477300)

Subjects:

Family clades associating with week to treatment, symptom score or FC. by Katrine Carlsen (5477300)

Subjects:

Alpha diversity measures across all 727 samples. by Katrine Carlsen (5477300)

Subjects:

Summary statistics for analysis of single genera clades. by Katrine Carlsen (5477300)

Subjects:

Abundance of the top 20 most abundant genera in one patient (Patient 1), across the weeks running up to treatment. by Katrine Carlsen (5477300)

Subjects:

Development of alpha diversity across weeks towards a new TNF treatment for each IBD disease subtype. by Katrine Carlsen (5477300)

Subjects:

Community composition of samples from five individuals show clustering of samples according to individual. by Katrine Carlsen (5477300)

Subjects:

Study taxonomy. by Katrine Carlsen (5477300)

Subjects:

Microbiome profile of the most abundant phyla in one patient (Patient 1), across 12 infliximab treatments (-1 is the week before treatment, -2 the two weeks before treatment, etc). by Katrine Carlsen (5477300)

Subjects:

S5 Fig - by Katrine Carlsen (5477300)

Subjects:

Summary statistics for analysis of single family clades. by Katrine Carlsen (5477300)

Subjects:

STORMS microbiome reporting checklist. by Katrine Carlsen (5477300)

Subjects:

Change in temperature from baseline. by Katharyn L. Flickinger (4759323)

Hemodynamic and respiratory changes over time. by Katharyn L. Flickinger (4759323)

Changes in relative abundance of genera in both therapeutic groups. by Flavia Furlaneto (20161022)

Flowchart of the study. by Flavia Furlaneto (20161022)

“…At genus level, an increase in the relative abundances of <i>Bergeyella</i> and <i>Corynebacterium</i> were significantly associated with a greater reduction in bleeding in the Placebo group and with less reduction in bleeding in the Probiotic group, respectively. …”